IMARC Group, a leading market research company, has recently releases report titled “Pharmacovigilance Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global pharmacovigilance market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights

How big is the pharmacovigilance market?

What is pharmacovigilance?

Pharmacovigilance (PV), also known as drug safety, refers to the science and activities involving the detection, assessment, understanding, and prevention of harmful effects and any other drug-related problems. It involves medicines and vaccines that undergo rigorous testing for safety and efficacy through clinical trials before they are authorized for use. It assists in creating, classifying, and reviewing PV data and creating more knowledge and awareness among healthcare professionals, patients, and the public. It also aids in understanding the effects of drugs on individuals. It can be tested clinically, epidemiologically, and experimentally to reproduce an adverse effect in animals and better understand the mechanism involved for human protection and diagnosis.

Request for a free sample copy of this report: https://www.imarcgroup.com/pharmacovigilance-market/requestsample

What are the growth prospects and trends in the pharmacovigilance?

The increasing occurrences of adverse drug reactions (ADRs) and drug toxicity on account of the rising frequency of lifestyle disorders, such as hypertension, diabetes, cancer, and cardiovascular disease (CVD), is resulting in the growing consumption of drugs. This represents one of the major factors positively influencing the demand for PV around the world. The demand of PV is also rising due to sedentary lifestyles, lack of physical activity, changing lifestyle patterns, and poor diets of individuals. In addition, the expanding number of airborne diseases on account of the rising air pollution levels is resulting in the growing utilization of PV. This, in confluence with the escalating demand for safe drugs and medicines, is bolstering the market growth. The rising aging population, which is more prone to these health ailments, is also contributing to the market growth. In addition, the increasing number of clinical trials by pharmaceutical companies is favoring the market growth.

Apart from this, there is a rise in the adoption of PV software to maintain safety data, minimize costs, and deliver best-practice monitoring and reporting workflows. The software is incorporated with advanced technologies, such as artificial intelligence (AI), machine learning (ML), cloud-based solutions, and end-to-end drug development technology to improve compliance and product safety in PV, which is providing lucrative growth opportunities to leading players operating in the industry. Besides this, several pharmaceutical, biotechnological and medical device companies are outsourcing PV operations to contract research organizations (CROs) on account of the rising awareness about their associated benefits, such as improving internal resource flexibility and better outcomes over shorter periods. This, in turn, is creating a positive outlook for the market. Furthermore, governing agencies of numerous countries are considerably investing in research and development (RD) projects and significant improvement in the healthcare infrastructure, which is projected to strengthen the growth of the market.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Service Provider:

• In-house
• Contract Outsourcing

Breakup by Product Life Cycle:

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Breakup by Type:

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

Breakup by Process Flow:

• Case Data Management
• Case Logging
• Case Data Analysis
• Medical Reviewing and Reporting
• Signal Detection
• Adverse Event Logging
• Adverse Event Analysis
• Adverse Event Review and Reporting
• Risk Management System
• Risk Evaluation System
• Risk Mitigation System

Breakup by Therapeutic Area:

• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others

Breakup by End Use:

• Pharmaceuticals Companies
• Biotechnology Companies
• Medical Device Companies
• Others

Breakup by Geography:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including:

• Accenture plc
• ArisGlobal LLC
• BioClinica Inc. (Cinven Partners LLP)
• Capgemini
• Cognizant
• International Business Machines Corporation
• ICON plc.
• IQVIA Inc.
• ITClinical
• Parexel International Corporation
• Wipro Limited

Ask Analyst for Customization and Browse full report with TOC List of Figure: https://www.imarcgroup.com/request?type=reportid=3609flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: sales@imarcgroup.com

Follow us on Twitter: @imarcglobal

LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/